BACKGROUND
Primary CNS lymphoma (PCNSL), is an uncommon form of non-Hodgkin's lymphoma (NHL) that is restricted to the central nervous system (CNS), involving only the brain, leptomeninges, spinal cord, cerebrospinal fluid (CSF), and/or eyes, with no other systemic involvement 1, 2 . 90% of PCNSLs are diffuse large B-cell lymphomas 1 , and can occur in patients with or without immunosuppression 3 .
Imaging modalities to investigate PCNSL include computed tomography (CT) and magnetic resonance imaging (MRI) scans. Typically, PCNSL lesions are detected in periventricular and superficial areas within the brain parenchyma 4 . On CT scans, these lesions appear iso-or hyperdense; on T1-weighted MRI scans they appear hypo-or isointense; whereas on T2-weighted MRI images they appear iso-or hyperintense lesions 4, 5 . Most of the CT and MRI lesions show moderate-to-marked contrast enhancement, mostly homogeneously enhancing lesions in patients without acquired immunodeficiency syndrome (AIDS), and peripherally-enhancing or ring-enhancing lesions in patients with AIDS 4 . Oedema and mass effect may also be found on imaging [4] [5] [6] .
However, these lesions on CT and MRI scans are not specific for PCNSL. Possibilities include other cerebral neoplasms namely glioblastomas 7, 8 , as well as infective causes such as neurocysticercosis 9 , brain tuberculomas 9 , cerebral toxoplasmosis 10 , cerebral abscess [11] [12] [13] , neurological Chagas disease (trypanosomiasis) 14 , cerebral actinomycosis 15 , coccidiomycosis 16 among others. Distinguishing these diagnoses by imaging alone is not easy, which is important given that the different conditions require different management protocols.
Since the chances of detecting peripherally-or ring-enhancing lesions are quite likely in clinical practice (due to its association with multiple diseases), it is important to realise the potential diagnostic dilemma they may cause.
Additionally, accurate and prompt diagnosis is essential to avoid unnecessary morbidity and mortality.
CASE PRESENTATION
We present a 21-year old gentleman of South Asian descent who came to the hospital after having a generalised tonic-clonic seizure, preceded by 2 days of headache and vomiting.
There was no history of fever. The patient had a similar seizure episode 1 year prior, but he was not investigated. Other than being an ex-smoker and having previous alcohol consumption, there was no other significant medical history.
On admission, he recovered relatively well after a short period of post-ictal confusion, with full conscious level and no neurological deficits. Initial blood tests were unremarkable apart from slight leucocytosis of 14,000/µL (normal range: 4,000 -10,000/µL), i.e. normal electrolytes, kidney and liver functions, inflammatory markers.
Initial computed tomography (CT) scan of the head revealed multiple peripherally-enhancing lesions with surrounding oedema, mass effect and midline shift of 3.5mm to the left side, as shown in Figure 1 (A & B) . This prompted the initiation of phenytoin as an anti-epileptic, along with dexamethasone to treat the cerebral oedema. Neurosurgical evaluation did not require urgent intervention to be carried out at that moment. Magnetic resonance imaging (MRI) of the brain was done which re-illustrated the CT findings of multiple lesions with surrounding oedema, see Figure At this point, considering the patient's history, demographics, and investigation results, a working diagnosis of either neurocysticercosis or brain tuberculomas was made. Empiric treatment was started, i.e. albendazole and antituberculous medications, along with steroids. Anti-epileptic medications were changed to levetiracetam to avoid drug interactions. As the patient was clinically asymptomatic, he was discharged home on the previously mentioned medications.
2 weeks later, he arrived at the emergency department with 2 days of headache and vomiting, along with multiple fainting episodes, night sweats and weight loss (4 kg over 2 weeks). There was no history of fever or cough.
Comparable to his previous presentation, initial neurological examination was unremarkable. As his symptoms did not improve, a repeat head CT scan was carried out, which showed worsening of the previous lesions, and increasing oedema, Due to progression of disease whilst on antihelminthic and anti-tuberculous management, other diagnoses had to be considered in this patient. Hence, MR Spectroscopy was done, which showed increased choline peak, decreased N-Acetyl Aspartate (NAA) peak, reversed choline/creatine ratio and high lipid/lactate peak. These findings are highly suggestive of lymphoma. Metastatic disease was a less likely possibility. As a staging CT scan of the thorax, abdomen and pelvis showed no suspicious deposits elsewhere, the patient was diagnosed with primary central nervous system (CNS) lymphoma.
After a multidisciplinary discussion, involving neurologists, neurosurgeons, and oncologists, it was decided to proceed with a brain biopsy,
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which was carried out approximately 3 weeks from the second presentation. During the procedure, it was noticed that the patient had unequal non-reactive pupils shortly after induction of anaesthesia, which prompted the neurosurgical team to perform a decompressive craniectomy together with the stereotactic brain biopsy. The patient recovered from surgery well, with resolution of anisocoria and conscious level.
Histopathological examination of the brain lesion was consistent with a diagnosis of large B cell lymphoma (with a differential diagnosis of follicular lymphoma). Immunohistochemistry (IHC) studies were positive for CD45, CD20, CD79a, MUM-1, BOB-1, BcL-2, BcL-6, and negative for CD3, CD5, EBV, CD-10 and GFAP. Ki-67 index was 70% and C-MYC was positive (~40%). Flow cytometry was consistent with CD10-positive mature B-cell neoplasm.
Haematology team was involved, and a multidisciplinary meeting was held, during which a decision was made to proceed for urgent lifesaving chemotherapy. Screening tests were unremarkable for HIV, hepatitis, syphilis, herpes simplex virus (HSV), cytomegalovirus (CMV), EBV, and toxoplasma. Full body fluorodeoxyglucose positron emission tomography (FDG PET) scan confirmed hypermetabolic foci in the brain, with no extracranial involvement. Bone marrow studies showed no lymphoma involvement.
Hence, the patient was started on the MATRix chemotherapy protocol (methotrexate, cytarabine, thiotepa, rituximab). Chemotherapy was well tolerated, with minimal side effects. No neurological deficits were noticed throughout the treatment period. The patient received 2 cycles of MATRix chemotherapy. He expressed his wishes to return to his home country and continue treatment there, with his family. Therefore, arrangements for travel were made, and patient underwent hypo-fractionated whole brain radiotherapy (30 Gy in 10 fractions, 3 Gy per fraction), which he tolerated well. MRI brain done after radiotherapy showed near complete resolution of the previous PCNSL lesions, as in Figure 2 (F & G) .
The following images show the sequence of MRI studies done on the patient throughout his illness and treatment course.
DISCUSSION
It can be seen in this case that primary CNS lymphoma is a diagnosis that may be missed, especially in a group of patients who, more often than not, have neurocysticercosis or brain tuberculomas, and present to the hospital in a similar manner. Moreover, initial imaging could reveal almost identical findings, which may not help in establishing the correct diagnosis, as can be seen below (Figure 3 to Figure 9 ).
The similar appearances of peripheral-or ringenhancing lesions in different conditions has been previously reported, especially in differentiating between neurocysticercosis and brain tuberculomas 9, 16, 17 . This diagnostic dilemma is made worse by the fact that less invasive tests cannot really exclude neurocysticercosis or brain tuberculomas. For example, there are no blood/CSF analyses that can exclude these diagnoses. A simple Mantoux test, or interferon-gamma (IFN-γ) release assays (IGRA), or even polymerase-chain reaction (PCR) tests for tuberculosis may be negative in certain tuberculous infections, including tuberculomas of the brain. Serological tests for neurocysticercosis, including enzymelinked immunosorbent assay (ELISA) and electroimmunotransfer blot (EITB), are also not 100% sensitive 18 . Only a histopathological analysis can provide diagnostic certainty.
It is worth noting that MR spectroscopy may provide insights to these brain lesions, and help distinguish the differential diagnoses to a certain extent. For example, most brain tumours show decreased N-acetyl aspartate (NAA) signals, increased choline (Cho), and hence increased Cho/NAA ratios 19 . Areas of ischaemia or infarction are likely to show increased lactate (due to anaerobic glycolysis), whereas gliomas show increased myo-inositol (mI) levels 19 .
Tuberculomas are associated with a lipid peak and decreased NAA 20 . In addition, TB lesions mostly show a singlet peak ~3.8ppm, which are not found in most malignancies 21 . On the other hand, high Cho/creatine (Cr) and mI/Cr ratios point towards malignancies rather than tuberculomas 21 . Neurocysticercosis lesions show a combination of increased lactate, alanine, succinate, Cho, but decreased NAA and Cr 20 .
Nevertheless, final diagnosis will require biopsy of the lesion. Other tests may be useful guides, as a confirmatory biopsy is an invasive procedure with its own risks. 
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